The Filing Desk

Protagonist Therapeutics vs Wave Life Sciences

Protagonist Therapeutics PTGX · Wave Life Sciences WVE · Biotechnology

Protagonist Therapeutics reported revenue of $46 million in fiscal 2025, about the same as Wave Life Sciences' $43 million in fiscal 2025. Protagonist Therapeutics' revenue fell 89.4% in its latest year, and Wave Life Sciences' fell 60.5%. Protagonist Therapeutics had an operating margin of -343.6%, against -504.1% at Wave Life Sciences. Free cash flow was $56 million at Protagonist Therapeutics and −$188 million at Wave Life Sciences.

Side by side

Protagonist TherapeuticsWave Life Sciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$46M$43M
Revenue growth−89.4%−60.5%
Revenue growth a year, last 5 years10.0%16.3%
Gross margin——
Operating margin−343.6%−504.1%
Net margin−282.8%−478.3%
Free cash flow$56M−$188M
Free cash flow margin121.9%−440.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count−2.3%22.0%
Last close$130.95$3.13
P/E at the last close27.8×—
Insider trades, last 12 monthssold $79.4 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Protagonist TherapeuticsWave Life Sciences
Operating margin
Percent of revenue
Protagonist TherapeuticsWave Life Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Protagonist TherapeuticsWave Life Sciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Protagonist Therapeutics and Wave Life Sciences pages.